Autopsy report · NCT00668681

Evaluation of EndoRefix Endovascular Delivery System and Staple

“Company business decision, IDE closed, no commercialization planned”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Lombard Medical

Sponsor type

Industry

Conditions

AAA Graft Implant for Primary Aneurysm Treatment; AAA Graft Repair to Extend Life of Implant

Interventions

EndoRefix

Participants

0

Sites

7

Countries

United States

Trials that died the same way

• Leptin in Human Energy and Neuroendocrine Homeostasis
  “Closed by sponsor. Lack of funding.” (59% match in meaning)
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
  “The development was stopped due to company's strategy consideration” (57% match in meaning)
• Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
  “Company business decision” (56% match in meaning)
• Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers
  “Product development project closed prematurely” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.